62 results about "Mediator" patented technology

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

The invention discloses a front door adjustment-based harmful modal cause detection depolarization method, which comprises the following steps of: constructing a structural causal model, creating a back door path between a modal cause and a harmful label by using unobserved confounding factors, and eliminating harmful modal cause detection through front door adjustment; the front door adjustment then blocks the back door path by introducing reasoning as an intermediary between the memetic and the tag. The method comprises the following steps: decomposing the causal effect of a medal factor on a harmful tag into the influence of the medal factor on an intermediary, quantifying by adopting a multi-modal large-scale language model with different beam searches to calculate the probability of each reasoning sequence and the influence of the intermediary on the tag, and performing effective approximation through a normalized weighted geometric averaging method; finally, post-interpretation is synthesized from the inference sequence and the predictive tag using a large language model. According to the scheme, the most advanced performance is achieved while information interpretation is provided.

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow / reperfusion damage.

The integrin family of cell adhesion molecules has emerged as key mediators of tissue fibrosis. A pharmacological inhibitor of multiple integrin subtypes is required to produce meaningful effects on delaying or inhibiting the progression of fibrosis. Monoclonal antibodies recognizing multiple integrins with potent neutralizing activity and having human and mouse cross-reactivity are described. In particular, monoclonal antibodies that bind human αvβ1, αvβ3, αvβ5, αvβ36, αvβ38, and α5β1 integrins and mouse αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 integrins are described.

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

Cas-protein-ready tau biosensor cells, CRISPR / Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

The invention discloses a sequence optimization method for improving the stability of circular RNA, application and a product, and belongs to the technical field of biotechnology and molecular biology. In order to solve the problem that the existing circular RNA is easy to be specifically degraded by RNAseK and lysosome after entering a cell, synonymous mutation optimization is carried out on an open reading frame of a target gene of the circular RNA by identifying nucleic acid motifs (a first type of nucleic acid motifs and a second type of nucleic acid motifs) identified by two degradation mechanisms. The optimized circular RNA is prepared by means of in-vitro cyclization of an anabaena I-type intron self-splicing mediator, after cells are transfected, the intracellular RNA expression level of the circular RNA is remarkably improved compared with that of a wild type, and the target protein expression efficiency is also remarkably improved. The intracellular stability and expression efficiency of the circular RNA are remarkably enhanced, and the method can be widely applied to the scenes of gene expression regulation, protein synthesis, gene therapy, vaccine development and the like.

This application relates to a biosensing electrode with sarcosine oxidase-directed modification, its preparation method, and its application in the field of biosensing technology. The biosensing electrode includes: a metal electrode, and a DNA-enzyme composite nanostructure connected to the metal electrode; the DNA-enzyme composite nanostructure includes a DNA electron transport module and an enzyme catalysis module; the DNA electron transport module includes a DNA sheet structure and a mediator embedded in the DNA sheet structure; the enzyme catalysis module includes a sarcosine oxidase substrate complex, which is connected to the DNA sheet structure; the sarcosine oxidase substrate complex, the mediator-containing DNA sheet structure, and the metal electrode are spatially ordered in the sequence of sarcosine oxidase substrate complex – mediator-containing DNA sheet structure – metal electrode. This biosensing electrode, under the condition of introducing a mediator, can improve the electron transport rate, thus exhibiting a good signal response during sarcosine testing.

Disclosed herein are circular RNAs and transfer mediators, as well as related compositions and methods of treatment. The circular RNA may comprise a Group I intron fragment, a spacer region, an IRES, a duplex forming region, and / or an expression sequence, thereby having characteristics of improved expression, functional stability, low immunogenicity, ease of manufacture, and / or prolonged half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and a transfer vehicle are particularly useful for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials that can be used to produce the precursor or circular RNA, which have improved cyclization efficiency and / or are compatible with an effective circular RNA purification process.

The present invention relates to detection reagents and electrode arrangements for multi-analyte diagnostic test elements and methods of use thereof. Detection reagents, multi-analyte test elements, test systems, and multi-analyte measurement methods are provided. In particular, a multi-analyte test element has (1) a first working electrode and a first counter electrode pair covered with a first analyte-specific reagent comprising an enzyme, a coenzyme and a first medium, and has (2) a second working electrode covered with a second analyte-specific reagent comprising an enzyme, a coenzyme and a second medium, where the second medium is different from the first medium. A single counter electrode may be used as a counter electrode for both first and second analyte measurements at their respective working electrodes. Further, the medium concentration, the measurement range, and the applied potential difference are different for each analyte-specific measurement.

Non-human animal cells and non-human animals comprising CRISPR / Cas synergistic activation mediator system components and methods of making and using such non-human animal cells and non-human animals are provided. Methods are provided for using such non-human animals to increase expression of target genes in vivo and to assess CRISPR / Cas synergistic activation mediator systems for the ability to increase expression of target genes in vivo.

A method for determining the presence of a molecule coupled to the cytoplasmic side of a cellular membrane is disclosed. The method is implemented in a microfluidic setting and is particularly suitable for determining the presence and / or the activity of a G protein or an arrestin protein in a cell.

This invention belongs to the field of medicine, specifically disclosing a drug-loaded biomimetic nanodecoy based on genetic engineering, its preparation method, and its application. The drug-loaded biomimetic nanodecoy of this invention comprises CCR2-overexpressing nanovesicles, and the hydrophobic regions of the nanovesicles are loaded with curcumin. This invention also provides a method for preparing the drug-loaded biomimetic nanodecoy based on genetic engineering and its application. The overexpressed CCR2 is used to adsorb excess CCL2 to inhibit the binding of macrophages to CCL2, preventing macrophage chemotaxis and subsequent TGF-β production. This inhibits the activation of hepatic stellate cells by removing pro-fibrotic mediators upstream; simultaneously, curcumin is released to block the downstream TGF-β / Smad signaling pathway, thereby inhibiting the activation of hepatic stellate cells.

The present invention provides complexes of a specialized pro-resolving mediator (SPM), or a salt, ester, or amide thereof, and a cyclodextrin (CD), wherein the SPM is a hydroxylated, polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length, with 4, 5 or 6 conjugated double bonds arranged in diene, triene, or tetraene systems or combinations thereof, and related compositions and methods.

1. The name of the design product: guide machine (dispute mediation). 2. The use of the design product: for self-service guidance, guide. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

This invention relates to the field of biodetection technology, specifically to a multimodal miRNA detection array based on Mn-CeO2@CDs nanozymes and Cas12a sensing, its preparation method, and its applications. The recognition and signal amplification probe composition based on Mn-CeO2@CDs nanozymes and Cas12a includes: a solid substrate, the DNA Y-shaped structure described in the first aspect, the composite nanozyme, and a CRISPR / Cas12a system. This invention combines DNA nanotechnology, Cas12a enzyme digestion technology, and nanozymes as signal output mediators, achieving highly specific and sensitive multimodal detection of myocarditis biomarkers (miRNAs) in fluorescence, UV-visualization, and electrochemical modes.

The invention discloses a deafness gene detection kit based on a molecular beacon and a medium probe and application, and relates to the technical field of molecular biology. The kit is used for single-tube detection of 15 mutation sites on four hereditary deafness genes, the detection kit comprises freeze-dried microspheres serving as standardized solid-state reagent units, the freeze-dried microspheres comprise specific primers, specific molecular beacons and specific medium probes, nucleotide sequences of the specific primers are shown as SEQ ID NO.35-SEQ ID NO.50, and nucleotide sequences of the specific molecular beacons and the specific medium probes are shown as SEQ ID NO.35-SEQ ID NO.50. The nucleotide sequences of the specific molecular beacons are as shown in SEQ ID NO.1 to SEQ ID NO.4, and the nucleotide sequences of the specific medium probes are as shown in SEQ ID NO.5 to SEQ ID NO.34. Compared with a traditional PCR technology, a chip technology and the like, the detection method provided by the invention can realize single-tube detection of different deafness genes, is simpler to operate, short in detection period and low in cost, and remarkably improves the detection sensitivity and accuracy.

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

The present invention is directed to chimeric antigen receptor (CAR) compositions and methods of their use in cancer and anti-viral immunotherapy. In particular, the CAR of the invention comprises a costimulatory signal (CSS) domain comprising herpes virus entry mediator protein (HVEM) or a functional fragment or variant thereof. CARs comprising such a HVEM CSS exhibit enhanced effector function.

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

The invention provides methods for treating, suppressing, or preventing detrimental cytokine and / or lipid mediator surges that can result from a variety of different diseases, conditions, and therapeutic treatments, e.g., by inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH).

A test strip with multiple electrochemical reaction blocks has multiple electrochemical reaction zone blocks but shares a sampling channel. However, it can suppress the structure of mediator diffusion and mutual interference in each reaction zone block. It includes plural detection electrodes, a first reaction zone and a second reaction zone. It uses the detection electrode in the first reaction zone to measure the hematocrit data of the analyte sample, at the same time, the detection electrode in the second reaction zone is used to read the reaction data generated by the analyte sample and the electrochemical mediator. These two data calculations for data compensation to correct the analyte concentration, avoiding measurement data deviation caused by the testing instrument due to different individual hematocrit ratios, and presenting the correct actual value of the analyte concentration.

The present invention provides peptides that specifically bind to maternal autoantibodies that are generated in the mother or potential mother against one or more endogenous polypeptide antigens selected from lactate dehydrogenase A (LDH A), lactate dehydrogenase B (LDH B), stress-induced phosphoprotein 1 (STIP1), guanine deaminase (GDA), Y Box Binding Protein 1 (YBX1), collapsin response mediator protein 1 (CRMP1), and collapsin response mediator protein 2 (CRMP2). The peptides described herein are useful for determining a risk of an offspring for developing an autism spectrum disorder (ASD) by detecting the presence of maternal autoantibodies in a biological sample of the mother or potential mother. The peptides or mimotopes thereof can also be administered to the mother or potential mother to block the binding between maternal autoantibodies and their antigens, thereby neutralizing the maternal autoantibodies.

A biosensor comprising an enzyme electrode that contains a conductive layer and a reagent layer adjacent to the conductive layer, wherein the conducive layer contains a mediator, and the reagent layer contains an amino acid oxidase and a cured product of a photosensitive polymer.

Provided herein, inter alia, are compositions including herpes virus entry mediator (HVEM) proteins and fragments thereof. The HVEM proteins provided herein may have modulated binding affinity to ligands and / or receptors compared to wild type HVEM proteins. The HVEM proteins provided herein are contemplated to be effective for treating diseases, particularly cancer and inflammatory diseases.

The instant disclosure provides chimeric protein constructs which comprise a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interacts with herpes virus entry mediator (HVEM) which enhances immune responses directed against the heterologous polypeptide. Also provided are compositions and methods of enhancing an immune response and treating a disease or disorder comprising said chimeric protein constructs.